Novartis’s Latecomer PD-1 Outshines Keytruda And Opdivo In Esophageal Cancer

Superior OS Results In Frontline Use

 
• By Andrew McConaghie

Novartis is playing catch-up in PD-1 inhibitors but could soon claim a best-in-class competitor in first-line esophageal cancer.

Basel, Switzerland - 27 August, 2016: sign on the wall of a Novartis building. Novartis International AG is a Swiss pharmaceutical company based in Basel, Switzerland.
Novartis does not expect to catch up with Keytruda and Opdivo in monotherapy, but is hoping to compete in the next generation of PD-1 based combination therapies. • Source: Shutterstock

More from Clinical Trials

More from R&D